Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex

被引:279
作者
Fuentes-Prior, P
Iwanaga, Y
Huber, R
Pagila, R
Rumennik, G
Seto, M
Morser, J
Light, DR
Bode, W
机构
[1] Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany
[2] Berlex Biosci, Richmond, CA 94804 USA
关键词
D O I
10.1038/35006683
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The serine proteinase alpha-thrombin causes blood clotting through proteolytic cleavage of fibrinogen and protease-activated receptors and amplifies its own generation by activating the essential clotting factors V and VIII1, Thrombomodulin(2), a transmembrane thrombin receptor with six contiguous epidermal growth factor-like domains (TME1-6), profoundly alters the substrate specificity of thrombin from pro- to anticoagulant by activating protein C (see, for example, reference 2). Activated protein C then deactivates the coagulation cascade by degrading activated factors V and VIII2. The thrombin-thrombomodulin complex inhibits fibrinolysis by activating the procarboxypeptidase thrombin-activatable fibrinolysis inhibitor(3). Here we present the 2.3 Angstrom crystal structure of human alpha-thrombin bound to the smallest thrombomodulin fragment required for full protein-C co-factor activity, TME456. The Y-shaped thrombomodulin fragment binds to thrombin's anion-binding exosite-I, preventing binding of procoagulant substrates. Thrombomodulin binding does not seem to induce marked allosteric structural rearrangements at the thrombin active site. Rather, docking of a protein C model to thrombin-TME456 indicates that TME45 may bind substrates in such a manner that their zymogen-activation cleavage sites are presented optimally to the unaltered thrombin active site.
引用
收藏
页码:518 / 525
页数:8
相关论文
共 38 条
[21]  
2-U
[22]  
KUROSAWA S, 1988, J BIOL CHEM, V263, P5993
[23]  
LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27
[24]   The interaction of thrombomodulin with Ca2+ [J].
Light, DR ;
Glaser, CB ;
Betts, M ;
Blasko, E ;
Campbell, E ;
Clarke, JH ;
McCaman, M ;
McLean, K ;
Nagashima, M ;
Parkinson, JF ;
Rumennik, G ;
Young, T ;
Morser, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 262 (02) :522-533
[25]   New insights into the regulation of the blood clotting cascade derived from the X-ray crystal structure of bovine meizothrombin des F1 in complex with PPACK [J].
Martin, PD ;
Malkowski, MG ;
Box, J ;
Esmon, CT ;
Edwards, BFP .
STRUCTURE, 1997, 5 (12) :1681-1693
[26]   The 2.8 angstrom crystal structure of Gla-domainless activated protein C [J].
Mather, T ;
Oganessyan, V ;
Hof, P ;
Huber, R ;
Foundling, S ;
Esmon, C ;
Bode, W .
EMBO JOURNAL, 1996, 15 (24) :6822-6831
[27]   STRUCTURE OF A NONADECAPEPTIDE OF THE 5TH EGF DOMAIN OF THROMBOMODULIN COMPLEXED WITH THROMBIN [J].
MATHEWS, II ;
PADMANABHAN, KP ;
TULINSKY, A ;
SADLER, JE .
BIOCHEMISTRY, 1994, 33 (46) :13547-13552
[28]   SYNTHESIS, ACTIVITY, AND PRELIMINARY STRUCTURE OF THE 4TH EGF-LIKE DOMAIN OF THROMBOMODULIN [J].
MEININGER, DP ;
HUNTER, MJ ;
KOMIVES, EA .
PROTEIN SCIENCE, 1995, 4 (09) :1683-1695
[29]   EVIDENCE FOR MULTIPLE CONFORMATIONAL-CHANGES IN THE ACTIVE-CENTER OF THROMBIN INDUCED BY COMPLEX-FORMATION WITH THROMBOMODULIN - AN ANALYSIS EMPLOYING NITROXIDE SPIN-LABELS [J].
MUSCI, G ;
BERLINER, LJ ;
ESMON, CT .
BIOCHEMISTRY, 1988, 27 (02) :769-773
[30]  
NAGASHIMA M, 1993, J BIOL CHEM, V268, P2888